Researchers from the Francis Crick Institute have found that some particularly aggressive lung cancer cells can develop their ...

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the ...

Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...

Rising air pollution, changes in hormone levels, immune system imbalances and longer life expectancy are increasing the risk ...

The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical ...

Lung ultrasound (LUS) may be an effective screening tool for interstitial lung disease in patients with asymptomatic rheumatoid arthritis.

The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...

A new blood test is designed to find mold infections deep inside the body, sparing patients from tissue biopsies.

Scientists uncover an enzyme that boosts cancer cell metabolism to fuel growth. The enzyme, GUK1, supports metabolism in cancer cells to help tumors grow.

The following is a summary of “Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...